Top Markets
#1 Nesa Nesa +824.17%
#2 Cortex Cortex +68.92%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.66%
#4 QuantixAI QuantixAI +24.05%
#5 EXOD EXOD +22.78%
#6 OpenEden OpenEden +20.79%
#7 Palladium Network Palladium Network +18.96%
#8 Pons Pons +17.38%
#9 Instadapp Instadapp +16.92%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +15.52%
Coin of the day
Nesa Nesa
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Prometheus Biosciences, Inc. Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc.

RXDX
Rang in aandelen #3433
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused... Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.
Aandeelprijs
$199.92
Laatst gesynchroniseerd: 2023-06-15
Marktkapitalisatie
$5.39B
Verandering (1 dag)
0.09%
Verandering (1 jaar)
0.00%
Land
US
Handel Prometheus Biosciences, Inc. (RXDX)

Categorie

Healthcare
Omzet van Prometheus Biosciences, Inc. (RXDX)
Omzet in Aug 2026 TTM: 0
Volgens de laatste financiële rapporten van Prometheus Biosciences, Inc. bedraagt de huidige omzet van het bedrijf (TTM) 0. In 2026 behaalde het bedrijf een omzet van 0 gelijk aan de omzet in het jaar 2026, die 0 bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Prometheus Biosciences, Inc. van 2026 tot 2026
Omzet aan het einde van elk jaar
Jaar Omzet Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Omzet van vergelijkbare bedrijven of concurrenten
Bedrijf Omzet Omzetverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH